UY24690A1 - Procedimiento para preparar un producto farmaceutico cristalino - Google Patents

Procedimiento para preparar un producto farmaceutico cristalino

Info

Publication number
UY24690A1
UY24690A1 UY24690A UY24690A UY24690A1 UY 24690 A1 UY24690 A1 UY 24690A1 UY 24690 A UY24690 A UY 24690A UY 24690 A UY24690 A UY 24690A UY 24690 A1 UY24690 A1 UY 24690A1
Authority
UY
Uruguay
Prior art keywords
water
bipiperidin
benzodiazepine
tetrahydro
oxo
Prior art date
Application number
UY24690A
Other languages
English (en)
Inventor
Torey Ross Stephen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of UY24690A1 publication Critical patent/UY24690A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un procedimiento para la preparación de una sal hidroclórica del ácido (S)-7-[(4,4'-bipiperidin-1-il)]-2,3,4,5-tetrahidro-4-metil-3-oxo-1H-1,4-benzodiacepina-2-acético, caracterizada por ser térmicamente estable, tener muy baja higroscopicidad, una estructura microcristalina y ser aproximadamente diez veces más soluble en agua que el zwitterion, donde el procedimiento comprende: a- formar una suspensión del ácdio (S)-7-[(4,4'-bipiperidin-1-il)carbonil]-2,3,4,5-tetrahidro-4-metil-3-oxo-1H-1,4-benzodiacepina-2-acético en agua; b- agregar gota a gota ácido clorhídrico, controlando el pH hasta lograr una solución amarillenta transparente; c- evaporar el agua a presión reducida, obteniendo una mesa vítrea; d- agitar y triturar dicha masa vítrea con etanol absoluto hasta obtener un sólido cristalino; e- filtrar y secar al aire. Esta invención comprende un método de antagonización del receptor de fibrinógeno para prevenir o tratar enfermedades en las que la agregación plaquetaria o la unión de ligando al receptor de fibrinógeno es un factor.
UY24690A 1996-09-03 1997-09-01 Procedimiento para preparar un producto farmaceutico cristalino UY24690A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2536996P 1996-09-03 1996-09-03

Publications (1)

Publication Number Publication Date
UY24690A1 true UY24690A1 (es) 1998-02-27

Family

ID=21825633

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24690A UY24690A1 (es) 1996-09-03 1997-09-01 Procedimiento para preparar un producto farmaceutico cristalino

Country Status (32)

Country Link
US (1) US6335330B1 (es)
EP (1) EP0964684B1 (es)
JP (1) JP2000517342A (es)
CN (1) CN1102391C (es)
AP (1) AP9901472A0 (es)
AR (1) AR008154A1 (es)
AT (1) ATE245984T1 (es)
AU (1) AU731173B2 (es)
BG (1) BG103196A (es)
BR (1) BR9711981A (es)
CA (1) CA2264607A1 (es)
CO (1) CO4930262A1 (es)
CZ (1) CZ71999A3 (es)
DE (1) DE69723873T2 (es)
DZ (1) DZ2302A1 (es)
EA (1) EA001363B1 (es)
ES (1) ES2205254T3 (es)
HU (1) HUP9904077A3 (es)
ID (1) ID18156A (es)
IL (1) IL128782A0 (es)
MA (1) MA24309A1 (es)
MY (1) MY118175A (es)
NO (1) NO991013D0 (es)
NZ (1) NZ334438A (es)
OA (1) OA10986A (es)
PE (1) PE107198A1 (es)
PL (1) PL332006A1 (es)
SK (1) SK27699A3 (es)
TR (1) TR199900480T2 (es)
UY (1) UY24690A1 (es)
WO (1) WO1998009629A1 (es)
ZA (1) ZA977870B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19902529A1 (de) * 1999-01-22 2000-08-03 Goldwell Gmbh Haarbehandlungsmittel
FR2797400A1 (fr) * 1999-08-11 2001-02-16 Sanofi Synthelabo Associations a activite anti-thrombotique constituees de l'hydrogenosulfate de clopidogrel et d'un antagoniste des recepteurs gpiib/iiia et les compositions pharmaceutiques les contenant
CN100560131C (zh) 2001-10-22 2009-11-18 斯克里普斯研究学院 抗体靶向化合物
US20050202151A1 (en) * 2004-03-15 2005-09-15 Land O'lakes, Inc. Method of preparing egg nuggets
KR101046977B1 (ko) * 2004-11-15 2011-07-07 삼성에스디아이 주식회사 카본나노튜브, 이를 포함한 전자 방출원 및 이를 구비한전자 방출 소자
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD138319A1 (de) * 1978-08-08 1979-10-24 Helmut Roehnert Verfahren zur herstellung einer stabilen,kristallwasser-und kristalloesungsmittelfreien kristallform des 7-chlor-2-methylamino-5-phenyl-3h-1,4-benzodiazepin-4-oxid-hydrochlorids
ES2190428T3 (es) 1991-06-28 2003-08-01 Smithkline Beecham Corp Antagonistas biciclicos de fibrinogeno.
US5939412A (en) 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
DE69332860T2 (de) 1992-12-21 2004-03-11 Smithkline Beecham Corp. Bicyklische fibrinogen antagoniste
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.

Also Published As

Publication number Publication date
NO991013L (no) 1999-03-02
AR008154A1 (es) 1999-12-09
EP0964684A1 (en) 1999-12-22
PL332006A1 (en) 1999-08-16
TR199900480T2 (xx) 1999-06-21
CN1102391C (zh) 2003-03-05
EP0964684B1 (en) 2003-07-30
DE69723873T2 (de) 2004-04-22
MY118175A (en) 2004-09-30
EP0964684A4 (en) 2002-05-29
HUP9904077A3 (en) 2002-03-28
AU4242597A (en) 1998-03-26
EA001363B1 (ru) 2001-02-26
JP2000517342A (ja) 2000-12-26
WO1998009629A1 (en) 1998-03-12
EA199900260A1 (ru) 1999-08-26
US6335330B1 (en) 2002-01-01
CN1234739A (zh) 1999-11-10
DZ2302A1 (fr) 2002-12-28
CO4930262A1 (es) 2000-06-27
AP9901472A0 (en) 1999-03-31
CA2264607A1 (en) 1998-03-12
BG103196A (en) 1999-09-30
ES2205254T3 (es) 2004-05-01
BR9711981A (pt) 1999-08-24
NZ334438A (en) 2000-10-27
OA10986A (en) 2003-03-04
HUP9904077A2 (hu) 2000-05-28
ID18156A (id) 1998-03-05
NO991013D0 (no) 1999-03-02
SK27699A3 (en) 2000-02-14
CZ71999A3 (cs) 1999-08-11
ATE245984T1 (de) 2003-08-15
ZA977870B (en) 1998-03-03
DE69723873D1 (de) 2003-09-04
PE107198A1 (es) 1999-03-21
MA24309A1 (fr) 1998-04-01
AU731173B2 (en) 2001-03-22
IL128782A0 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
DK1227806T3 (da) Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
EA013973B1 (ru) Способы лечения кожной волчанки при помощи аминоизоиндолиновых соединений
ATE304528T1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
AR056468A1 (es) Formulaciones de ibandronato mejoradas
NO166448C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiazolidindioner.
TNSN06226A1 (en) Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
AU3261799A (en) Inorganic nitrite and organic acid in combination as topical antiviral composition
BR9916361A (pt) Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
IL75536A0 (en) Pseudomonic acid salt,its preparation and pharmaceutical and veterinary compositions comprising it
CA2392050A1 (en) Pharmaceutical formulations containing zolmitriptan
UY24690A1 (es) Procedimiento para preparar un producto farmaceutico cristalino
EP1001759B1 (en) Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
DE69217511T2 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
EG19302A (en) Compound with gastric acid inhibitory effect and process for its preparation
ATE116849T1 (de) Pharmazeutische verwendung von fettsäuren.
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
Zhang et al. Effects of prostaglandin E1 on human keratinocytes and dermal fibroblasts: a possible mechanism for the healing of skin ulcers
CA2544432A1 (en) Stable pharmaceutical composition comprising granulocyte-colony stimulating factor
PE20040916A1 (es) Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13
DE60226225D1 (de) Phtalazine derivate mit angiogenesis inhibierender wirkung
DE60008293D1 (de) Pharmazeutische zusammensetzung die einen no donor enthält und dessen therapeutische anwendung

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20170901